Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

corporate strategy

- PMLiVE

Novartis gets speedy reviews for new Kymriah filings

US and EU regulatory agencies will review the drug for DLBCL patients

- PMLiVE

Novartis joins biosimilar Humira push in US

Pharma giant hopes its candidate will follow in the footsteps of Amgen’s Amjevita and BI’s Cyltezo

- PMLiVE

Pfizer’s Elizabeth Barrett joins Novartis as its oncology head

She succeeds Bruno Strigini who retires

- PMLiVE

Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown

The head-to-head trials will evaluate findings in patients with PsA and AS

- PMLiVE

Novartis’ Promacta receives US breakthrough therapy designation

Regulatory filings of the rare blood disorder treatment are expected this year

- PMLiVE

Novartis bags new breakthrough status for Kisqali in breast cancer

The Swiss pharma group’s treatment will rival Lilly’s Verzenio and Pfizer’s Ibrance if approved

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

Novartis Oncology head Bruno Strigini to retire

Will leave the Swiss pharma firm, and the industry, next year

- PMLiVE

CAR-T therapies show long-term benefits in lymphoma

Novartis’ Kymriah and Gilead’s Yescarta both achieve significant complete response in lymphoma patients

- PMLiVE

AAA board presses go on $3.9bn Novartis takeover

French radiopharmaceuticals firm backs the cash offer

- PMLiVE

Novartis’ orphan drug Tasigna wins EU expanded indication

The CML medication can now treat paediatric patients

National Institute for Health and Care Excellence NICE logo

NICE backs two advanced breast cancer drugs after price cuts

An estimated 8,000 women will be eligible to receive the drugs due to discounts

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links